Transgenomic, Inc. (NASDAQ:TBIO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Transgenomic, Inc. (NASDAQ:TBIO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Story continues below

Item 5.02

Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers, 2017 Stock Award and
Incentive Plan.

As previously reported on June 6, 2017, at the 2017 Special
Meeting of Stockholders of Transgenomic, Inc. (the Company) held
on June 5, 2017, the Companys stockholders approved the
Transgenomic, Inc. 2017 Stock Option and Incentive Plan (the
Plan). A description of the material terms of the Plan is set
forth on pages 100 through 106 of the Companys Definitive Proxy
Statement on Schedule 14A, which was filed with the Securities
and Exchange Commission on May 12, 2017 and is incorporated
herein by reference. The description of the Plan and of the
awards agreements thereunder is qualified in its entirety by
reference to the Plan, the Form of Non-Qualified Stock Option
Agreement for Non-Employee Directors, the Form of Non-Qualified
Stock Option Agreement for Company Employees and the Form of
Incentive Stock Option Agreement, which are attached hereto as
Exhibits 10.1 through 10.4 respectively, and which are
incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

See the Exhibit Index immediately following the page hereto,
which is incorporated herein by reference.



TRANSGENOMIC INC Exhibit
EX-10.1 2 v469811_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1   TRANSGENOMIC,…
To view the full exhibit click here
About Transgenomic, Inc. (NASDAQ:TBIO)

Transgenomic, Inc. is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment. The Company is engaged in the provision of its Multiplexed ICE COLD-PCR (MX-ICP) product to the clinical market, enabling the use of blood and other bodily fluids for diagnosis, monitoring and treatment of cancer. MX-ICP amplifies the ability to detect genetic mutations by approximately 100 to 400 fold. MX-ICP is validated internally on sequencing platforms, including Sanger, Next Gen Sequencing and Digital polymerase chain reaction (PCR). Its laboratory in Omaha, Nebraska is focused on providing genetic analytical services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies.

An ad to help with our costs